CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 99 enrolled
Drug / intervention
MP-513 +2 moredrug
Likely dose
MP-513 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01072331
NCT01072331Phase 3Completed
CompareCT.gov

Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus

Tanabe Pharma Corporation·interventional·Posted Feb 22, 2010·Updated Jan 2, 2026

In Brief

A Phase 3 clinical trial evaluating MP-513 and Placebo of MP-513 for Type 2 Diabetes Mellitus. Completed, enrolled 99 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2010
Enrollment StartFeb 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.4 years ago

Interventions

MP-513drug

MP-513 10 mg, once a day, for 4 weeks

MP-513drug

MP-513 20 mg, once a day, for 4 weeks

Placebo of MP-513drug

MP-513 placebo, once a day, for 4 weeks